Sorrento Therapeutics, Inc. · OTC:SRNE
Sorrento Therapeutics — Technical Presentation (January 2022)
13 slides from Sorrento Therapeutics's technical presentation, Jan 21, 2022
Slide 1: Sorrento Potent Omicron Neutralizing Antibody (nAb) STI-9167 IV STI-9199 IN
Sorrento Potent Omicron Neutralizing Antibody (nAb) STI - 9167 IV STI - 9199 IN Exhibit 99.1
Slide 2: Disclaimer
Disclaimer Certain statements contained in this presentation or in other documents of Sorrento Therapeutics, Inc . (the “Company”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward - look
Slide 3: Discovery of STI-9167
Discovery of STI - 9167 3 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 4: Binding to S1 Domain of Variants of Concern (VOCs)
STI - 9167 Binding to S1 Domain of SARS - CoV - 2 Variants of Concern (VOCs) 4 Analyte: WA - 1, Delta, or Omicron spike S1 domain Instrument: Biacore T200 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 5: Binding Kinetics to Spike S1 Domain Compared to Those of EUA-approved nAbs
STI - 9167 Binding Kinetics to Spike S1 Domain Compared to Those of EUA - approved nAbs 5 Analyte: Omicron spike S1 domain Instrument: Biacore T200 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 6: Binding to VOC Spike Proteins Expressed on HEK293 Cells
STI - 9167 Binding to SARS - CoV - 2 VOC Spike Proteins Expressed on HEK293 Cells 6 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 7: Omicron Variant and Omicron + R346K Mutation Infection Statistics
Omicron Variant and Omicron + R346K Mutation Infection Statistics 7 To date: No SARS - CoV - 2 nAb approved or in development has been shown to have potent neutralization activity (≤ 100 ng/ml) against the Omicron + R346K variant © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, d
Slide 8: Spike-Pseudotyped VSV Neutralization Assay
SARS - CoV - 2 Spike - Pseudotyped VSV Neutralization Assay 8 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 9: Superior Neutralization Activities Against Omicron and Omicron+R346K Variants
STI - 9167 Superior Neutralization Activities Against Omicron and Omicron+R346K Variants in SARS - CoV - 2 Spike - Pseudotyped VSV Neutralization Assays 9 Variant Lineage STI - 9167 Cilgavimab (AZ) Tixagevimab (AZ) D614G 0.0036 0.0353 0.0056 Omicron (B.1.1.529) 0.0148 9.105 0.6386 Omicron+R346K (B.1
Slide 10: Neutralization Activity in the Live Virus Neutralization Assays
Neutralization Activity of STI - 9167 in the SARS - CoV - 2 Live Virus Neutralization Assays 10 © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission.
Slide 11: Superior Neutralization Activity as Compared to EUA-approved nAbs in Live Omicron Virus Assays
Superior Neutralization Activity of STI - 9167 as Compared to EUA - approved Neutralization Antibodies (nAbs) in the SARS - CoV - 2 Live Omicron Virus Neutralization Assays 11 1 10 100 1000 0 25 50 75 100 Omicron ng/ml F R N T ( % ) Tixagevimab Cilgavimab Bamlanivimab + Etesevimab Sotrovimab STI-916
Slide 12: Neutralizing Activity Following IN or IV Administration in K18-hACE2 Mouse Model
STI - 9167 Neutralizing Activity Following IN or IV Administration in the K18 - hACE2 Transgenic Mouse Model of COVID - 19 12 RSV mAb = negative control RSV mAb = negative control © 2022 Sorrento Therapeutics, Inc. All Rights Reserved. Do not copy, distribute, or reproduce without express permission
Slide 13: GMP Manufacturing and Clinical Developmental Status
STI - 9167 GMP Manufacturing and Clinical Developmental Status 13 x STI - 9167 GMP Master Cell Bank generation completed x IND - enabling preclinical safety and toxicology studies completed • Phase 1 clinical trials planned in healthy individuals and infected patients for both intranasal formulation
Sorrento Therapeutics — Technical Presentation (January 2022) on 6ix